Multi-institutional registry study evaluating the feasibility and toxicity of accelerated partial breast irradiation using noninvasive image-guided breast brachytherapy |
| |
Authors: | Jaroslaw T. Hepel Kara L. Leonard Mark Rivard Rashmi Benda Ann Pittier Dean Mastras Sandra Sha Leann Smith Michael Kerley Paul G. Kocheril Tushar R. Shah Andrea McKee John Chinault Bushra Rana David E. Wazer |
| |
Affiliation: | 1. Department of Radiation Oncology, Rhode Island Hospital, Brown University, Providence, RI;2. Department of Radiation Oncology, Tufts Medical Center, Tufts University, Boston, MA;3. Department of Radiation Oncology, Lynn Cancer Institute, Boca Raton, FL;4. Department of Radiation Oncology, Tacoma Valley Radiation, Tacoma, WA;5. Department of Radiation Oncology, Watson Clinic, Lakeland, FL;6. Department of Radiation Oncology, Cancer Centers of Southwest Oklahoma, Lawton, OK;7. Department of Radiation Oncology, Genesys Hurley Cancer Institute, Flint, MI;8. Department of Radiation Oncology, Lahey Clinic, Burlington, MA;9. Department of Radiation Oncology, Mary Washington Hospital, Fredericksburg, VA |
| |
Abstract: | PurposeThe noninvasive image-guided breast brachytherapy (NIBB) technique is a novel noninvasive yet targeted method for accelerated partial breast irradiation. We established a multi-institutional registry to evaluate the toxicity and efficacy of this technique across various practice settings.Methods and MaterialsInstitutions using the NIBB technique were invited to participate. Data for acute/late toxicity, cosmetic outcome, and tumor recurrence were collected. Toxicity and cosmetic outcome were graded based on the Common Terminology Criteria for Adverse Events version 3.0 and NRG/Radiation Therapy Oncology Group scale, respectively. Treatment variables were analyzed for association with outcomes.ResultsA total of 252 patients from eight institutions were analyzed. The median age was 69 years. The mean tumor size was 1.1 cm (0.1–4.0 cm). Treatment was delivered 10 fractions (34–36 Gy) in 75% and five fractions (28.5 Gy) in 22%. B.i.d. fractionation was used in 9%. Acute radiation dermatitis was Grade 0–1, 2, and 3 in 77%, 19%, and 4%, respectively. One hundred ninety-one patients with a median followup of 18 months (4–72 months) were evaluable for late outcomes. Late toxicity Grades 2 and 3 were observed in 8.8% and 1%, respectively. Cosmetic outcome was excellent, good, and fair/poor in 62%, 36%, and 2%, respectively. B.i.d. fractionation was associated with higher acute and late toxicity. Second-generation applicators were associated with lower late toxicity and better cosmetic outcome. Actuarial freedom from ipsilateral breast tumor recurrence and true recurrence were 98.3% and 98.3% at 2 years and 90.9% and 95.4% at 5 years, respectively.ConclusionsAccelerated partial breast irradiation using NIBB was well tolerated with a low rate of acute and late toxicity across various practice settings. Ipsilateral breast tumor recurrence and cosmetic outcomes were favorable. b.i.d. fractionation was associated with higher toxicity. Longer followup is needed to confirm late endpoints. |
| |
Keywords: | Breast cancer Brachytherapy Partial breast irradiation APBI Noninvasive image-guided breast brachytherapy NIBB |
本文献已被 ScienceDirect 等数据库收录! |
|